Loading...
BFNH
OTCM
Market cap255mUSD
Nov 20, Last price  
6.70USD
1D
-3.74%
1Q
83.46%
IPO
9,336.62%
Name

BioForce Nanosciences Holdings Inc

Chart & performance

D1W1MN
OTCM:BFNH chart
P/E
—
P/S
—
EPS
—
Vol. 1Y
354.88%
Shs. 5Y
15.29%
Rev. 5Y
-63.44%
Div Yld LY
—
Div Yld TTM
—
Revenues
0
699,082808,859137,592139,770415,0871,125,030026,71206,0758,2504,50016,31017,775000000
Net income
-1m
L+163.43%
-834,928-1,284,029-1,186,271-2,092,488-3,974,083-3,854,206-4,30122,161-2,500-2,500-5,712-31,261-67,738-46,538-158,408,555-501,955-485,514-471,953-490,437-1,291,951
CFO
-65k
L+6.37%
-960,254-1,213,371-1,274,913-1,588,688-2,655,003-2,747,933022,161001,750-25,898-62,466-24,383-80,196-77,772-68,389-46,702-61,250-65,150

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

BioForce Nanosciences Holdings, Inc. (BFNH) specializes in providing natural vitamins, minerals, and a variety of other nutritional supplements, along with powders and beverages, intended for individuals across all age demographics. The firm also operates in the private label market, collaborating with both distributors and production partners. Under its BioForce Eclipse brand, BFNH's dietary supplements reach consumers through a broad network of retailers, including general merchandise stores, sporting goods shops, grocery chains, and large mass merchandisers. Additionally, the company facilitates sales directly via its online presence and telemarketing campaigns. Its corporate base is situated in Virginia Beach, Virginia.

Key people

Sasha Shapiro
President · since 2021
Steven Gagnon
Co-Chief Executive Officer · since 2021
John La Violette
Co-Chief Executive Officer · since 2021
Merle Ferguson
Chairman of the Board · since 2021
Chief Financial Officer, Secretary, Director · since 2016
IPO date
Oct 11, 2005
Employees
3
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT